OTCMKTS:PHGUF Pharming Group Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Pharming Group Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.13 0.00 (0.00 %) (As of 09/30/2020 12:00 AM ET) Add Compare Share Today's Range$1.13Now: $1.13▼$1.1350-Day Range$1.09MA: $1.22▼$1.2952-Week Range$0.83Now: $1.13▼$1.82VolumeN/AAverage Volume13,054 shsMarket Capitalization$704.12 millionP/E Ratio16.07Dividend YieldN/ABeta1.66 ProfileAnalyst RatingsChartCompetitorsEarningsHeadlinesShort Interest Pharming Group N.V., a specialty pharmaceutical company, develops and produces human therapeutic proteins for the treatment of rare diseases and unmet medical needs. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of angioedema attacks in patients with acute hereditary angioedema (HAE) in Europe, the United States, Israel, European Union countries, Norway, Iceland, and Liechtenstein. It also engages in the development of recombinant human C1 inhibitor for treating HAE attacks; and recombinant human factor VIII (rhFVIII), a natural human blood clotting factor for treating haemophilia A. The company has a strategic collaboration with Shanghai Institute of Pharmaceutical Industry for the development, manufacture, and commercialization of new products based on the Pharming technology platform; and a partnership agreement with the China State Institute of Pharmaceutical Industry for the development of rhFVIII for the treatment of Haemophilia A. Pharming Group N.V. is headquartered in Leiden, the Netherlands.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Pharming Group. Previous Next 2.2 Community Rank Outperform VotesPharming Group has received 171 “outperform” votes. (Add your “outperform” vote.)Underperform VotesPharming Group has received 215 “underperform” votes. (Add your “underperform” vote.)Community SentimentPharming Group has received 55.70% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Pharming Group and other stocks. Vote “Outperform” if you believe PHGUF will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PHGUF will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldPharming Group does not currently pay a dividend.Dividend GrowthPharming Group does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Pharming Group insiders have not sold or bought any company stock. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Pharming Group are expected to grow by 37.50% in the coming year, from $0.08 to $0.11 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pharming Group is 16.07, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 18.69.Price to Earnings Ratio vs. SectorThe P/E ratio of Pharming Group is 16.07, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 27.27.Price to Book Value per Share RatioPharming Group has a P/B Ratio of 5.92. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 2.5 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.94 out of 5 stars Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Tobacco products Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:PHGUF Previous SymbolOTC:PHGUF CUSIPN/A CIKN/A Webwww.pharming.com Phone31-0-71-524-7400Debt Debt-to-Equity Ratio1.00 Current Ratio4.45 Quick Ratio4.08Price-To-Earnings Trailing P/E Ratio16.07 Forward P/E Ratio14.06 P/E GrowthN/A Sales & Book Value Annual Sales$189.30 million Price / Sales3.72 Cash Flow$0.07 per share Price / Cash Flow16.61 Book Value$0.19 per share Price / Book5.92Profitability EPS (Most Recent Fiscal Year)$0.06 Net Income$40.54 million Net Margins22.82% Return on Equity37.38% Return on Assets15.32%Miscellaneous Employees183 Outstanding Shares625,880,000Market Cap$704.12 million Next Earnings Date10/22/2020 (Estimated) OptionableNot Optionable $1.13 0.00 (0.00 %) (As of 09/30/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive PHGUF News and Ratings via Email Sign-up to receive the latest news and ratings for PHGUF and its competitors with MarketBeat's FREE daily newsletter. Pharming Group (OTCMKTS:PHGUF) Frequently Asked Questions How has Pharming Group's stock price been impacted by Coronavirus (COVID-19)? Pharming Group's stock was trading at $1.35 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, PHGUF shares have decreased by 16.7% and is now trading at $1.1250. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Pharming Group? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pharming Group in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Pharming Group. When is Pharming Group's next earnings date? Pharming Group is scheduled to release its next quarterly earnings announcement on Thursday, October 22nd 2020. View our earnings forecast for Pharming Group. How were Pharming Group's earnings last quarter? Pharming Group (OTCMKTS:PHGUF) posted its quarterly earnings data on Thursday, July, 30th. The biotechnology company reported $0.02 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.01 by $0.01. The biotechnology company had revenue of $43.35 million for the quarter, compared to analyst estimates of $56.33 million. Pharming Group had a return on equity of 37.38% and a net margin of 22.82%. View Pharming Group's earnings history. Who are some of Pharming Group's key competitors? Some companies that are related to Pharming Group include LONZA GRP AG/ADR (LZAGY), Imperial Tobacco Group (IMBBY), Turning Point Brands (TPB), Standard Diversified Inc Class A (NYSEAMERICAN) (SDI), Healthier Choices Management (HCMC) and Gilla (GLLA). View all competitors. Who are Pharming Group's key executives? Pharming Group's management team includes the following people: Dr. Sijmen de Vries M.D., MBA, Chairman of Management Board & CEO (Age 60)Mr. Robin Wright BA (Oxon), FCA., CFO & Member of Management Board (Age 55)Dr. Bruno M. L Giannetti, COO & Member of Management Board (Age 67)Dr. Pericles Calias, Chief Scientific Officer (Age 51)Ms. Anne-Marie de Groot, Sr. VP of Organisational Devel. (Age 38) What is Pharming Group's stock symbol? Pharming Group trades on the OTCMKTS under the ticker symbol "PHGUF." How do I buy shares of Pharming Group? Shares of PHGUF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Pharming Group's stock price today? One share of PHGUF stock can currently be purchased for approximately $1.13. How big of a company is Pharming Group? Pharming Group has a market capitalization of $704.12 million and generates $189.30 million in revenue each year. The biotechnology company earns $40.54 million in net income (profit) each year or $0.06 on an earnings per share basis. Pharming Group employs 183 workers across the globe. What is Pharming Group's official website? The official website for Pharming Group is www.pharming.com. How can I contact Pharming Group? Pharming Group's mailing address is Darwinweg 24, Leiden P7, 2333 CR. The biotechnology company can be reached via phone at 31-0-71-524-7400 or via email at [email protected] This page was last updated on 10/1/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
